linjc16/ctgov huggingface dataset:
Huntsman Biopsy Study

Study Overview
=================
Brief Summary
-----------------
Bone and soft tissue sarcomas are currently classified based upon light microscopy supplemented by immunohistochemistry, but within many if not all of these tumor histologic types, considerable heterogeneity exists not only in microscopic appearance but also in biologic behavior and prognosis. Progress in the directed treatment of these tumors, particularly the sarcomas, awaits characterization of the gene profiles for these tumors. Orthopedic oncology researchers at Huntsman Cancer Institute at the University of Utah are establishing a tumor bank for this purpose. The long term objectives of this work include: creating tumor specific gene profiles to improve diagnostic accuracy performing gene set validation for diagnostic predictive power defining a discriminate gene list implicated in pathogenesis The tissue procured under this protocol at SUNY Upstate Medical University will be limited to excess soft tissue and bone tumor tissue from patients otherwise undergoing clinically indicated procedures for diagnosis or treatment under the care of the local principal investigator (PI) and will be forwarded to the central investigator, R. Lor Randall, MD at Huntsman Cancer Institute for use in the characterization of the gene profiles of these tumors.

Detailed Description
-----------------
as stated in brief summary

Official Title
-----------------
The Huntsman Cancer Institute - The Use of Microarray Analysis in Characterizing Mesenchymal Tissue Tumors: Differentiation of Normal, Benign, and Malignant Conditions

Conditions
-----------------
Soft Tissue Sarcoma, Osteosarcoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Bone or soft tissue tumor that has been established to be or is suspected to possibly be a sarcoma AND who will require a diagnostic or therapeutic surgical procedure which will result in procurement of tissue for histologic review Exclusion Criteria: Non cancer patients
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Soft tissue tumor<br>Any patient with soft tissue tumor will be asked to give a sample for this study | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Classification of sarcomas | sarcomas will be classified by researchers at Huntsman Institute | Upon collection/analysis of sarcoma | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Create tumor specific gene profiles to improve diagnostic accuracy, Perform gene set validation for diagnostic predictive power, Define deviant gene list implicated in pathogenesis
The Association Between Central Aortic Blood Pressure Indices and Severity of Coronary Artery Disease

Study Overview
=================
Brief Summary
-----------------
Abstract Objectives: Primary: To study the association between central aortic blood pressure indices and coronary artery disease in patients undergoing elective angiography. Secondary: (a) To study whether any association exists between central aortic pressure indices and the incidence of major adverse cardiovascular events (MACE) in the same patients during a 6 month follow up period. (b) To study whether any association exists between the central aortic pressures and peripheral pressures. Methods: The investigators conducted a prospective observational study in consecutive patients undergoing coronary angiography. Central and peripheral pressures were invasively recorded and coronary artery disease (CAD) classified into obstructive and non-obstructive group. CAD severity was graded using the Gensini score and subjects were divided into tertiles. Patients were followed up and the role of central aortic pressure indices in the prediction of cardiovascular events were analysed.

Official Title
-----------------
The Association Between Central Aortic Blood Pressure Indices and Severity of Coronary Artery Disease

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Procedure: CORONARY ANGIOGRAM AND CENTRAL AORTIC WAVEFORM ANALYSIS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing elective angiography for diagnosis of CAD. Age > 18 years Exclusion Criteria: Patients with acute myocardial infarction, unstable angina or thromboembolism in the preceding 3 months. More than mild valvular heart disease. Renal impairment with serum creatinine > 1.5 mg%. Unable to obtain a full study of the coronary arteries. Peripheral vascular occlusive disease. Post coronary artery bypass grafting( CABG) Heart rate < 50/min and > 120/min and other arrhythmias. Contraindications for coronary angiography. Unable to provide written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: CORONARY ANGIOGRAM AND CENTRAL AORTIC WAVEFORM ANALYSIS|coronary angiogram|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| acute coronary syndrome(ACS) |  | 6 MONTHS | 
| stroke |  | 6 months | 
| revascularisation |  | 6 months | 
| death |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
central pressure, Gensini score, pulsatility, coronary artery disease
Predictors of Severe COVID-19 Outcomes

Study Overview
=================
Brief Summary
-----------------
This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes, primarily acute respiratory distress syndrome (ARDS) and/or mortality, in patients presenting to the hospital with suspicion or diagnosis of COVID-19. We seek to understand whether there are early signatures that predict progression to ARDS, mortality, and/or other comorbid conditions. The duration of the study participation is approximately 3 months.

Official Title
-----------------
Predictors of Severe COVID-19 Outcomes (PRESCO)

Conditions
-----------------
Acute Respiratory Distress Syndrome, COVID-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participant or legally authorized representative willing and able to provide informed consent Receiving care at a participating site Age 18 years old or older U.S. Resident Confirmed positive for COVID-19 Willing and able to comply with all study procedures Exclusion Criteria: Self reported pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Performance (discrimination / calibration) of models | Performance (discrimination / calibration) of models that predict the risk of development of ARDS and/or mortality among COVID-19 patients who present to the hospital for evaluation and treatment. | From date of study enrollment until the date of first documented ARDS diagnosis or date of death from any cause, whichever comes first, assessed up to study end (estimated at 3 months). |
Efficacy and Tolerance of a Follow-On Formula Fed to Children From 12-48 Months of Age in Salvador, Bahia, Brazil

Study Overview
=================
Brief Summary
-----------------
The purpose is to determine if the consumption of study product has an effect on acute respiratory infections and/or diarrheal disease.

Conditions
-----------------
Acute Respiratory Infection, Diarrheal Disease

Intervention / Treatment
-----------------
* Dietary Supplement: Cow's milk
* Dietary Supplement: Follow-On Formula


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Child 12-48 months of age Has consumed cow's milk or a cow's milk-based beverage during the 48 hours prior to randomization Signed informed consent Exclusion Criteria: Child who is receiving predominantly breast-milk Child who received any food product or supplement containing probiotics or prebiotics in the 15 days prior to randomization Child with allergy to gluten or serious concurrent illness that will interfere in the general management of the child Child with diarrhea or acute respiratory infection during the 48 hours prior to randomization Child's z-score of weight for length/height < -3 according to World Health Organization criteria

Ages Eligible for Study
-----------------
Minimum Age: 12 Months
Maximum Age: 48 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Cow's Milk<br>Powdered Whole Cow's Milk | Dietary Supplement: Cow's milk<br>* Powdered Whole Cow's Milk<br>|
| Experimental: Follow-On Formula<br>Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide | Dietary Supplement: Follow-On Formula<br>* Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Episodes of acute respiratory infections and diarrheal disease |  | 28 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of allergic manifestations |  | 28 weeks | 
| Systemic antibiotic use |  | 28 weeks | 
| Duration of acute respiratory infection and diarrheal disease |  | 28 weeks | 
| Changes in stool patterns |  | 28 weeks | 
| Fecal and serum immune markers |  | 28 weeks | 
| Serum Ferritin and Zinc status |  | 28 weeks | 
| Incidence of stool parasites |  | 28 weeks | 
| Growth |  | 28 weeks | 
| Incidence of adverse events | The incidence of any adverse event for each participant | 28 weeks | 
| Acceptance of study product | Acceptance of study product based on quantity consumed | 28 weeks |
The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry

Study Overview
=================
Brief Summary
-----------------
By creating a neurogenebank from Parkinson's disease patients' blood donations we will ultimately be able to define genes for Parkinson's disease and other neurological conditions.

Official Title
-----------------
The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry

Conditions
-----------------
Parkinson's Disease

Intervention / Treatment
-----------------
* Other: There is no intervention, this is a biorepository.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Is age 30 years or older at the time of onset of Parkinson's Has been diagnosed with idiopathic Parkinson's Disease by a Scripps Neurologist Is reliable, cooperative and willing to comply with all protocol-specified procedures and/or sub-study if consented or have legal representative/guardian willing to do so Able to understand and grant informed consent or have a legal representative/ guardian who is able to do so Exclusion Criteria: Patient has been previously enrolled in The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry If a blood draw would be contraindicated for any reason Has a significant chronic medical condition (i.e. CVA, hepatic encephalopathy) which, in the investigator's option, may interfere with the patient's optimal participation in the study Treatment with any investigational agents or devices within 30 days preceding enrollment in the study Has undergone ECT within 90 days preceding enrollment in the study

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Treatment<br> | Other: There is no intervention, this is a biorepository.<br>* There are no interventions in this study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neurogenetic databank | initiate a Parkinson's disease neurogenetic databank by obtaining blood samples in order to define genes for Parkinson's disease and other neurological conditions. | Study completion |
Cardiovascular Risk Factors After Renal Transplantation in Children and Adults

Study Overview
=================
Brief Summary
-----------------
Renal transplantation of children started in Norway in 1970.Since the beginning, >80% of renal transplants are provided from Living Donors(mainly parents), short pre-transplant dialysis time( median 4 months) and 50% of transplantations are performed before dialysis is needed.This gives good premises for graft survival and avoidance of detrimental effects of dialysis. However, renal transplanted children are subjected to an increased cardiovascular morbidity and mortality in adulthood due to consequences of chronic renal failure and immunosuppressive treatment.Cardiovascular death comprises 30-40% of death causes. In this cross-sectional study we evaluate cardiovascular risk factors in childhood- and also in young adults renal transplanted in childhood. Focus is cardiorespiratory fitness using treadmill testing,24h BP measurements, anthropometrics including waist circumference,echocardiography,intima media thickness of carotids, glucose intolerance test.Participants are also requested to fill out physical activity recalls and Quality of life questionnaires.

Official Title
-----------------
Outcome After Pediatric Renal Transplantation: Cardiorespiratory Fitness, Cardiovascular Risk Factors and Quality of Life

Conditions
-----------------
Exercise Capacity, Physical Activity, Hypertension, Overweight and Obesity, Metabolic Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Transplanted after 1983, functioning graft Exclusion Criteria: Patients in dialysis In part of the study concerning treadmill testing: Age<8 years, orthopedic limitations

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 38 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Renal transplanted children and young adults<br>Renal transplanted children and adolescents (2-18yrs) transplanted between 1993-2006. Renal transplanted young adults aged 20-35 yrs old, transplanted from 1983 onwards. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| other cardiovascular risk factors |  | 2007-2010 | 
| hypertension |  | 2007-2010 | 
| impaired glucose intolerance |  | 2007-2010 | 
| left ventricular hypertrophy, |  | 2007-2010 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiorespiratory fitness, physical activity, hypertension, overweight and obesity, metabolic syndrome, Body composition
Measurement of Eye Movements While Reading a German Text

Study Overview
=================
Brief Summary
-----------------
To establish normative value for reading parameters in healthy children of primary school age and in grades 2-5.

Detailed Description
-----------------
Following initial assessment of feasibility, recruitment is expanded to children attending grades 2-5 recruited from 4 different primary schools in German speaking Switzerland. Two texts of The New International Reading Speed Test (IReST) of similar difficulty are presented on a laptop in randomized order. Children are asked to read the text aloud while eye movements are recorded with an eye tracking bar. The following parameters are analysed: reading speed (words/minute), number of saccades, number of fixations.

Official Title
-----------------
Measurement of Eye Movements While Reading a German Text

Conditions
-----------------
Healthy Children

Intervention / Treatment
-----------------
* Diagnostic Test: reading of a text


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 8-13 years child consent parental consent Exclusion Criteria: unability to read

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 13 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| healthy children aged 8-13years (schoolgrade 2-5)<br>Primary school children are asked to read a German text presented on a laptop screen | Diagnostic Test: reading of a text<br>* Reading of 2 IRest Texts presented on a laptop in randomized order while eye movements are recorded with a tracking bar.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reading speed | words read per minute | 21 months | 
| number of saccades and fixations | how stable are the eyes while reading out loud | 21 months |
Surpass Flow Diverter for Intracranial Aneurysms: SURMOUNT Registry Data Collection

Study Overview
=================
Brief Summary
-----------------
The purpose of this observational post-marketing registry will be to collect and analyze safety, effectiveness, and quality of life outcomes, during and after treatment with the Surpass Flow Diverter. Health Economics assessments (cost data) will also be collected and analyzed.

Detailed Description
-----------------
This will be a prospective, observational, multi-center, single-arm, post-marketing, international registry with consecutive enrollment of a minimum of 150 patients treated with the Surpass Flow Diverter in accordance with the standard of care at up to 30 registry sites.

Official Title
-----------------
Prospective, Observational, Multi-Center, Single-Arm, Consecutive Enrollment, Post-Marketing, International Registry of the Surpass™ Flow Diverter in Intracranial Arteries

Conditions
-----------------
Cerebral Aneurysm

Intervention / Treatment
-----------------
* Device: Surpass Flow Diverter(s)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are to be treated with a Surpass Flow Diverter(s) will be eligible to participate in this registry. Patients will be enrolled on a consecutive basis. Exclusion Criteria: This is a standard of care registry. Patients should be excluded if standard of care at a given site is such that they are not eligible for treatment with a Surpass Flow Diverter(s).
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Single Group; Surpass Flow Diverter(s)<br>Individuals using the Surpass Flow Diverter(s) | Device: Surpass Flow Diverter(s)<br>* Endovascular placement of a Surpass Flow Diverter(s) for the treatment of an intracranial aneurysm(s)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary effectiveness based on the proportion of patients with 100% aneurysm occlusion | The proportion of patients with 100% aneurysm occlusion, based on an assessment of each patient's imaging at 12 months (± 180 days) post-procedure, and stratified across four aneurysm categories. | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Technical success assessed by deployment of the device with complete coverage of the aneurysm neck | Successful deployment of the device with complete coverage of the aneurysm neck. | Peri-procedural |